Legend Capital
Mr. Hong joined Legend Capital in 2008 as Associate, and was later promoted to Vice President, Director, and Executive Director. He is now Managing Director of the firm and focuses on healthcare investments.
Mr. Hong has rich experience in the pharmaceutical industry and investment in Healthcare sectors. The investment portfolios he has led include Innovent Biologics (01801.HK), Kawin Technology, PegBio, Baheal Pharmaceutical, Sciwind Biologics, Ribo, dMed etc.
Prior to Legend Capital, Mr. Hong worked at ShiYu Capital, Nanjing University of Traditional Chinese Medicine, and Bayer Healthcare.
Mr. Hong holds a Bachelor's degree from China Pharmaceutical University and a MBA from Tongji University.
This person is not in any offices
Legend Capital
1 followers
In April 2001, Legend Capital was formed, and set up its first fund with US$35 mn commitment from Legend Holdings. Now Legend Capital is the independent Venture Capital investment subsidiary under the holdings company. In February 2012, Legend Capital took the new Chinese name "君联(Junlian)".